Literature DB >> 8721669

A reappraisal of ganglioside GD3 expression in the CNS.

J E Goldman1, R Reynolds.   

Abstract

GD3 ganglioside is a major glycolipid component of the developing central nervous system but diminishes considerably as the CNS matures. Despite consistent biochemical data, the cellular localization of GD3 expression has been controversial. In this commentary we will review the cellular expression of GD3 during CNS development and in neuropathological circumstances as determined by studies with the two most commonly used anti GD3 monoclonal antibodies, R24 and LB1. GD3 is not restricted to any one cell lineage, being expressed in development to varying degrees by immature neuroectodermal cells, oligodendrocyte progenitors, ameboid microglia, and subpopulations of developing neurons and astrocytes. In the adult CNS, GD3 is expressed in low amounts by some neuronal subpopulations, on reactive and resting microglia, and by reactive astrocytes. In the appropriate contexts of development or neuropathology, anti-GD3 antibodies are useful for cell type identification and for cell isolation, but caution should be exercised because of the lack of cellular specificity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721669     DOI: 10.1002/(SICI)1098-1136(199604)16:4<291::AID-GLIA1>3.0.CO;2-3

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  9 in total

Review 1.  Cell reactions following acute brain injury: a review.

Authors:  W T Norton
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

2.  Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons.

Authors:  Agata Copani; Daniela Melchiorri; Andrea Caricasole; Francesca Martini; Patrizio Sale; Roberto Carnevale; Roberto Gradini; Maria Angela Sortino; Luisa Lenti; Ruggero De Maria; Ferdinando Nicoletti
Journal:  J Neurosci       Date:  2002-05-15       Impact factor: 6.167

3.  Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro.

Authors:  Valeriya K Khurdayan; Shreya Buch; Nazira El-Hage; Sarah E Lutz; Susan M Goebel; Indrapal N Singh; Pamela E Knapp; Jadwiga Turchan-Cholewo; Avindra Nath; Kurt F Hauser
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

4.  The changing phenotype of microglia from homeostasis to disease.

Authors:  Xiao-Guang Luo; Sheng-Di Chen
Journal:  Transl Neurodegener       Date:  2012-04-24       Impact factor: 8.014

5.  Prevalence of IgG Autoantibodies against GD3 Ganglioside in Acute Zika Virus Infection.

Authors:  Dirlei Nico; Luciana Conde; Juan L Rivera-Correa; Andréia Vasconcelos-Dos-Santos; Louise Mesentier-Louro; Leonardo Freire-de-Lima; Mônica Barcellos Arruda; Celio Geraldo Freire-de-Lima; Orlando da Costa Ferreira; Maria Elisabeth Lopes Moreira; Andrea Araújo Zin; Zilton Farias Meira Vasconcelos; Rosalia Mendez Otero; Clarisa Beatriz Palatnik-de-Sousa; Amilcar Tanuri; Adriane Regina Todeschini; Wilson Savino; Ana Rodriguez; Alexandre Morrot
Journal:  Front Med (Lausanne)       Date:  2018-03-09

6.  Gangliosidome of a Human Hippocampus in Temporal Lobe Epilepsy Resolved by High-Resolution Tandem Mass Spectrometry.

Authors:  Raluca Ica; Kristina Mlinac-Jerkovic; Katarina Ilic; Tomislav Sajko; Cristian V A Munteanu; Alina D Zamfir; Svjetlana Kalanj-Bognar
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

7.  Ganglioside GD3 is up-regulated in microglia and regulates phagocytosis following global cerebral ischemia.

Authors:  Jing Wang; Quanguang Zhang; Yujiao Lu; Yan Dong; Krishnan M Dhandapani; Darrell W Brann; Robert K Yu
Journal:  J Neurochem       Date:  2021-07-07       Impact factor: 5.546

8.  Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson's Disease.

Authors:  T N Seyfried; H Choi; A Chevalier; D Hogan; Z Akgoc; J S Schneider
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

Review 9.  O-acetylated Gangliosides as Targets for Cancer Immunotherapy.

Authors:  Sumeyye Cavdarli; Philippe Delannoy; Sophie Groux-Degroote
Journal:  Cells       Date:  2020-03-17       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.